Gemcitabine versus modified gemcitabine: A review of several promising chemical modifications

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 430-444

  Moysan, Elodie ^a,b   Bastiat, Guillaume ^a,b   Benoit, Jean Pierre ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

antitumor effect; chemical modification; gemcitabine; prodrug; resistance

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CYTARABINE; DOCETAXEL; ELACYTARABINE; FLUOROURACIL; GEMCITABINE; GEMCITABINE ELAIDATE; GEMCITABINE TRIPHOSPHATE; IDARUBICIN; LY 2334737; MACROGOL; NEO 6002; PACLITAXEL; PEGAMOTECAN; SORAFENIB; SQUALENE; SYNTHETASE; THYMIDINE PHOSPHATE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TRANSPORT; GENE EXPRESSION REGULATION; HUMAN; LIPOPHILICITY; LIPOSOMAL DELIVERY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SQUALENOYLATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, BIOLOGICAL; PHOSPHORYLATION; PRODRUGS;

EID: 84873367277     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300370t     Document Type: Review

References (128)

1. Carmichael, J.; Fink, U.; Russell, R. C.; Spittle, M. F.; Harris, A. L.; Spiessi, G.; Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer Br. J. Cancer 1996, 73, 101-105 (Pubitemid 26026268)
2. Hoang, T.; Kim, K.; Jaslowski, A.; Koch, P.; Beatty, P.; McGovern, J.; Quisumbing, M.; Shapiro, G.; Witte, R.; Schiller, J. H. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Lung Cancer 2003, 42, 97-102 (Pubitemid 37153141)
3. Yardley, D. A. Gemcitabine plus paclitaxel in breast cancer Semin. Oncol. 2005, 32 (4 Suppl 6) S14-21
4. Ozols, R. F. Gemcitabine and carboplatin in second-line ovarian cancer Semin. Oncol. 2005, 32 (4 Suppl 6) S4-8
5. Rauchwerger, D. R.; Firby, P. S.; Hedley, D. W.; Moore, M. J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity Cancer Res. 2000, 60, 6075-6079
6. Farrell, J. J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W. F.; Abrams, R.; Benson, A. B.; Macdonald, J.; Cass, C. E.; Dicker, A. P.; Mackey, J. R. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 2009, 136, 187-195
7. Duxbury, M. S.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine Oncogene 2004, 23, 1539-1548 (Pubitemid 38406516)
8. Zacchigna, M.; Cateni, F.; Drioli, S.; Bonora, G. M. Multimeric, multifunctional derivatives of poly(ethylene glycol) Polymers 2011, 3, 1076-1090
9. Lundberg, B. B.; Risovic, V.; Ramaswamy, M.; Wasan, K. M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration J. Controlled Release 2003, 86, 93-100 (Pubitemid 35461976)
10. Bergman, A. M.; Kuiper, C. M.; Voorn, D. A.; Comijn, E. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines Biochem. Pharmacol. 2004, 67, 503-511 (Pubitemid 38232890)
11. Bianchi, V.; Borella, S.; Calderazzo, F.; Ferraro, P.; Chieco Bianchi, L.; Reichard, P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8403-8407
12. Stathis, A.; Moore, M. J. Advanced pancreatic carcinoma: current treatment and future challenges Nat. Rev. Clin. Oncol. 2010, 7, 163-172
13. Eli Lilly and Company Gemzar (Gemcitabine HCL) for injection 2005. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b-11-04- KP%20GemcitabineFDAlabel42005.pdf; accessed 10-8-2012.
14. Eli Lilly and Company Annual Report and Proxy Statement 2010. http://files.shareholder.com/downloads/LLY/2107551369x0x447905/ 6281D413-C258-488B-ADBE-B35289495F26/English.PDF; accessed 10-8-2012.
15. Reid, J. M.; Qu, W.; Safgren, S. L.; Ames, M. M.; Krailo, M. D.; Seibel, N. L.; Kuttesch, J.; Holcenberg, J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors J. Clin. Oncol. 2004, 22, 2445-2451 (Pubitemid 41115403)
16. Abbruzzese, J. L.; Grunewald, R.; Weeks, E. A.; Gravel, D.; Adams, T.; Nowak, B.; Mineishi, S.; Tarassoff, P.; Satterlee, W.; Raber, M. N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J. Clin. Oncol. 1991, 9, 491-498
17. Griffith, D. A.; Jarvis, S. M. Nucleoside and nucleobase transport systems of mammalian cells Biochim. Biophys. Acta 1996, 1286, 153-181 (Pubitemid 26426520)
18. Paproski, R. J.; Ng, A. M.; Yao, S. Y.; Graham, K.; Young, J. D.; Cass, C. E. The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine Mol. Pharmacol. 2008, 74, 1372-1380
19. Ueno, H.; Kiyosawa, K.; Kaniwa, N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer. 2007, 97, 145-151 (Pubitemid 47057479)
20. Hodge, L. S.; Taub, M. E.; Tracy, T. S. Effect of its deaminated metabolite, 2′,2′-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells Biochem. Pharmacol. 2011, 81, 950-956
21. Mori, R.; Ishikawa, T.; Ichikawa, Y.; Taniguchi, K.; Matsuyama, R.; Ueda, M.; Fujii, Y.; Endo, I.; Togo, S.; Danenberg, P. V.; Shimada, H. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells Oncol. Rep. 2007, 17, 1201-1205
22. Giovannetti, E.; Del Tacca, M.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini, C.; Boggi, U.; Campani, D.; Del Chiaro, M.; Iannopollo, M.; Bevilacqua, G.; Mosca, F.; Danesi, R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res. 2006, 66, 3928-3935
23. Plunkett, W.; Huang, P.; Gandhi, V. Preclinical characteristics of gemcitabine Anticancer Drugs 1995, 6, 7-13 (Pubitemid 26014890)
24. Barton-Burke, M. Gemcitabine: a pharmacologic and clinical overview Cancer Nurs. 1999, 22, 176-183 (Pubitemid 29352696)
25. Heinemann, V.; Xu, Y. Z.; Chubb, S.; Sen, A.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res. 1992, 52, 533-539
26. Jansen, R. S.; Rosing, H.; Schellens, J. H. M.; Beijnen, J. H. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundam. Clin. Pharmacol. 2011, 25, 172-185
27. Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) Drug Resist. Updat. 2002, 5, 19-33
28. Komori, S.; Osada, S.; Mori, R.; Matsui, S.; Sanada, Y.; Tomita, H.; Tokuyama, Y.; Takahashi, T.; Yamaguchi, K.; Yoshida, K. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer Pancreas 2010, 39, 1284-1292
29. Ruiz van Haperen, V. W.; Veerman, G.; Vermorken, J. B.; Peters, G. J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem. Pharmacol. 1993, 46, 762-766 (Pubitemid 23262974)
30. Clarke, M. L.; Mackey, J. R.; Baldwin, S. A.; Young, J. D.; Cass, C. E. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs Cancer Treat. Res. 2002, 112, 27-47
31. Maréchal, R.; Mackey, J. R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C. E.; Young, J.; Salmon, I.; DevieÌre, J.; Van Laethem, J.-L. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin. Cancer Res. 2009, 15, 2913-2919
32. Santini, D.; Schiavon, G.; Vincenzi, B.; Cass, C. E.; Vasile, E.; Manazza, A. D.; Catalano, V.; Baldi, G. G.; Lai, R.; Rizzo, S.; Giacobino, A.; Chiusa, L.; Caraglia, M.; Russo, A.; Mackey, J.; Falcone, A.; Tonini, G. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) Curr. Cancer Drug Targets 2011, 11, 123-129
33. Sebastiani, V.; Ricci, F.; Rubio-Viqueira, B.; Kulesza, P.; Yeo, C. J.; Hidalgo, M.; Klein, A.; Laheru, D.; Iacobuzio-Donahue, C. A. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival Clin. Cancer Res. 2006, 12, 2492-2497
34. Zhou, B. S.; Tsai, P.; Ker, R.; Tsai, J.; Ho, R.; Yu, J.; Shih, J.; Yen, Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential Clin. Exp. Metastasis 1998, 16, 43-49 (Pubitemid 28122554)
35. Zhou, J.; Oliveira, P.; Li, X.; Chen, Z.; Bepler, G. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J. Nucleic Acids 2010, 597098.
36. Fujita, H.; Ohuchida, K.; Mizumoto, K.; Itaba, S.; Ito, T.; Nakata, K.; Yu, J.; Kayashima, T.; Souzaki, R.; Tajiri, T.; Manabe, T.; Ohtsuka, T.; Tanaka, M. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy Neoplasia 2010, 12, 807-817
37. Tolis, C.; Peters, G.; Ferreira, C. G.; Pinedo, H. M.; Giaccone, G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines Eur. J. Cancer 1999, 35, 796-807 (Pubitemid 29258151)
38. Costantino, C. L.; Witkiewicz, A. K.; Kuwano, Y.; Cozzitorto, J. A.; Kennedy, E. P.; Dasgupta, A.; Keen, J. C.; Yeo, C. J.; Gorospe, M.; Brody, J. R. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR-upregulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase Cancer Res. 2009, 69, 4567-4572
39. Richards, N. G.; Rittenhouse, D. W.; Freydin, B.; Cozzitorto, J. A.; Grenda, D.; Rui, H.; Gonye, G.; Kennedy, E. P.; Yeo, C. J.; Brody, J. R.; Witkiewicz, A. K. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients Ann. Surg. 2010, 252, 499-505
40. 505-506.
41. Storniolo, A. M.; Allerheiligen, S. R.; Pearce, H. L. Preclinical, pharmacologic, and phase I studies of gemcitabine Semin. Oncol. 1997, 24 (2 Suppl 7) S7-2-7-7
42. Mero, A.; Clementi, C.; Veronese, F. M.; Pasut, G. Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods Methods Mol. Biol. 2011, 751, 95-129
43. Pasut, G.; Veronese, F. M. State of the art in PEGylation: The great versatility achieved after forty years of research J. Controlled Release 2012, 161, 461-472
44. Pasut, G.; Veronese, F. M. PEG conjugates in clinical development or use as anticancer agents: An overview Adv. Drug Delivery Rev. 2009, 61, 1177-1188
45. Sawant, R. M. Polyethylene glycol (peg) as a key component of long-circulating delivery systems for therapy and imaging Pharm. Sci. Dissert. 2008, 1-107
46. Caliceti, P.; Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 2003, 55, 1261-1277 (Pubitemid 37464561)
47. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284 (Pubitemid 30122932)
48. Szebeni, J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity Toxicology 2005, 216, 106-121 (Pubitemid 41712000)
49. Liu, J.; Zahedi, P.; Zeng, F.; Allen, C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel J. Pharm. Sci. 2008, 97, 3274-3290
50. Li, C.; Yu, D.; Inoue, T.; Yang, D. J.; Milas, L.; Hunter, N. R.; Kim, E. E.; Wallace, S. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug Anticancer Drugs 1996, 7, 642-648 (Pubitemid 26348842)
51. Vandana, M.; Sahoo, S. K. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer Biomaterials 2010, 31, 9340-9356
52. Chuang, K.-H.; Wang, H.-E.; Chen, F.-M.; Tzou, S.-C.; Cheng, C.-M.; Chang, Y.-C.; Tseng, W.-L.; Shiea, J.; Lin, S.-R.; Wang, J.-Y.; Chen, B.-M.; Roffler, S. R.; Cheng, T.-L. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy Mol. Cancer Ther. 2010, 9, 1903-1912
53. Bareford, L. M.; Swaan, P. W. Endocytic mechanisms for targeted drug delivery Adv. Drug Delivery Rev. 2007, 59, 748-758 (Pubitemid 47320813)
54. Pasut, G.; Canal, F.; Dalla Via, L.; Arpicco, S.; Veronese, F. M.; Schiavon, O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid J. Controlled Release 2008, 127, 239-248
55. Basal, E.; Eghbali-Fatourechi, G. Z.; Kalli, K. R.; Hartmann, L. C.; Goodman, K. M.; Goode, E. L.; Kamen, B. A.; Low, P. S.; Knutson, K. L. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients PLoS ONE 2009, 4, e6292
56. Iwakiri, S.; Sonobe, M.; Nagai, S.; Hirata, T.; Wada, H.; Miyahara, R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers Ann. Surg. Oncol. 2008, 15, 889-899
57. Hartmann, L. C.; Keeney, G. L.; Lingle, W. L.; Christianson, T. J.; Varghese, B.; Hillman, D.; Oberg, A. L.; Low, P. S. Folate receptor overexpression is associated with poor outcome in breast cancer Int. J. Cancer 2007, 121, 938-942 (Pubitemid 47101628)
58. Shmeeda, H.; Amitay, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Ogorka, J.; Kumar, S.; Zhang, J. A.; Gabizon, A. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells J. Controlled Release 2010, 146, 76-83
59. Yang, S.-J.; Lin, F.-H.; Tsai, K.-C.; Wei, M.-F.; Tsai, H.-M.; Wong, J.-M.; Shieh, M.-J. Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells Bioconjugate Chem. 2010, 21, 679-689
60. Kaaki, K.; Herve, K.; Chiper, M.; Shkilnyy, A.; Soucé, M.; Benoit, R.; Paillard, A.; Dubois, P.; Saboungi, M.-L.; Chourpa, I. Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability and cancer cell targeting Langmuir 2011, 28, 1496-1505
61. Schiavon, O.; Pasut, G.; Moro, S.; Orsolini, P.; Guiotto, A.; Veronese, F. M. PEG-Ara-C conjugates for controlled release Eur. J. Med. Chem. 2004, 39, 123-133 (Pubitemid 38249525)
62. Dauty, E.; Remy, J.-S.; Zuber, G.; Behr, J.-P. Intracellular delivery of nanometric DNA particles via the folate receptor Bioconjugate Chem. 2002, 13, 831-839 (Pubitemid 34801126)
63. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discovery 2003, 2, 214-221 (Pubitemid 37361666)
64. Bender, D. M.; Bao, J.; Dantzig, A. H.; Diseroad, W. D.; Law, K. L.; Magnus, N. A.; Peterson, J. A.; Perkins, E. J.; Pu, Y. J.; Reutzel-Edens, S. M.; Remick, D. M.; Starling, J. J.; Stephenson, G. A.; Vaid, R. K.; Zhang, D.; McCarthy, J. R. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine J. Med. Chem. 2009, 52, 6958-6961
65. Koolen, S. L.; Witteveen, P. O.; Jansen, R. S.; Langenberg, M. H.; Kronemeijer, R. H.; Nol, A.; Garcia-Ribas, I.; Callies, S.; Benhadji, K. A.; Slapak, C. A.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors Clin. Cancer Res. 2011, 17, 6071-6082
66. Huang, Z.-R.; Lin, Y.-K.; Fang, J.-Y. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology Molecules 2009, 14, 540-554
67. Kelly, G. S. Squalene and its potential clinical uses Altern. Med. Rev. 1999, 4, 29-36 (Pubitemid 29205159)
68. Newmark, H. L. Squalene, olive oil, and cancer risk: a review and hypothesis Cancer Epidemiol. Biomarkers Prev. 1997, 6, 1101-1103 (Pubitemid 28007424)
69. Couvreur, P.; Stella, B.; Reddy, L. H.; Hillaireau, H.; Dubernet, C.; Desmaële, D.; Lepeître-Mouelhi, S.; Rocco, F.; Dereuddre-Bosquet, N.; Clayette, P.; Rosilio, V.; Marsaud, V.; Renoir, J.-M.; Cattel, L. Squalenoyl nanomedicines as potential therapeutics Nano Lett. 2006, 6, 2544-2548 (Pubitemid 46076946)
70. Desmaële, D.; Gref, R.; Couvreur, P. Squalenoylation: A generic platform for nanoparticular drug delivery J. Controlled Release 2012, 161, 609-618
71. Jordheim, L. P.; Cros, E.; Gouy, M.-H.; Galmarini, C. M.; Peyrottes, S.; Mackey, J.; Perigaud, C.; Dumontet, C. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion on in vitro resistance by a mononucleotide prodrug Clin. Cancer Res. 2004, 10, 5614-5621 (Pubitemid 39100503)
72. Gourdeau, H.; Clarke, M. L.; Ouellet, F.; Mowles, D.; Selner, M.; Richard, A.; Lee, N.; Mackey, J. R.; Young, J. D.; Jolivet, J.; LafrenieÌre, R. G.; Cass, C. E. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines Cancer Res. 2001, 61, 7217-7224 (Pubitemid 32946518)
73. Reddy, L. H.; Dubernet, C.; Mouelhi, S. L.; Marque, P. E.; Desmaële, D.; Couvreur, P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types J. Controlled Release 2007, 124, 20-27 (Pubitemid 350103730)
74. Réjiba, S.; Reddy, L. H.; Bigand, C.; Parmentier, C.; Couvreur, P.; Hajri, A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer Nanomedicine 2011, 7, 841-849
75. Pili, B.; Reddy, L. H.; Bourgaux, C.; Lepeître-Mouelhi, S.; Desmaële, D.; Couvreur, P. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation Nanoscale 2010, 2, 1521-1526
76. Arias, J. L.; Reddy, L. H.; Othman, M.; Gillet, B.; Desmaële, D.; Zouhiri, F.; Dosio, F.; Gref, R.; Couvreur, P. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics ACS Nano 2011, 5, 1513-1521
77. Bildstein, L.; Dubernet, C.; Marsaud, V.; Chacun, H.; Nicolas, V.; Gueutin, C.; Sarasin, A.; Bénech, H.; Lepeître-Mouelhi, S.; Desmaële, D.; Couvreur, P. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway J. Controlled Release 2010, 147, 163-170
78. Podgorski, I.; Sloane, B. F. Cathepsin B and its role(s) in cancer progression Biochem. Soc. Symp. 2003, 70, 263-276 (Pubitemid 38497232)
79. Yang, Z.; Cox, J. L. Cathepsin L increases invasion and migration of B16 melanoma Cancer Cell Int. 2007, 7, 8
80. Celia, C.; Cosco, D.; Paolino, D.; Fresta, M. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity Expert Opin. Drug Deliv. 2011, 8, 1609-1629
81. Dosio, F.; Reddy, L. H.; Ferrero, A.; Stella, B.; Cattel, L.; Couvreur, P. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation Bioconjugate Chem. 2011, 21, 1349-1361
82. Jantscheff, P.; Ziroli, V.; Esser, N.; Graeser, R.; Kluth, J.; Sukolinskaya, A.; Taylor, L. A.; Unger, C. Massing, U. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model Clin. Exp. Metastasis 2009, 26, 981-992
83. Aggarwal, S.; Yadav, S.; Gupta, S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer J. Biomed. Nanotechnol. 2011, 7, 137-138
84. Yang, F.; Jin, C.; Yang, D.; Jiang, Y.; Li, J.; Di, Y.; Hu, J.; Wang, C.; Ni, Q.; Fu, D. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment Eur. J. Cancer 2011, 47, 1873-1882
85. Ventura, C. A.; CannavaÌ, C.; Stancanelli, R.; Paolino, D.; Cosco, D.; La Mantia, A.; Pignatello, R.; Tommasini, S. Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation Biomed. Microdevices 2011, 13, 799-807
86. Stella, B.; Arpicco, S.; Rocco, F.; Marsaud, V.; Renoir, J. M.; Cattel, L.; Couvreur, P. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules Int. J. Pharmaceutics 2007, 344, 71-77 (Pubitemid 47464827)
87. Arya, G.; Vandana, M.; Acharya, S.; Sahoo, S. K. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy Nanomedicine 2011, 7, 859-870
88. Cattel, L.; Ceruti, M.; Dosio, F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy Tumori 2003, 89, 237-249 (Pubitemid 37014112)
89. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M.; Madden, T. D. Liposomal Encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res. 2000, 60, 3389-3393 (Pubitemid 30482152)
90. Milla, P.; Dosio, F.; Cattel, L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery Curr. Drug Metab. 2012, 13, 105-109
91. Immordino, M. L.; Brusa, P.; Rocco, F.; Arpicco, S.; Ceruti, M.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Controlled Release 2004, 100, 331-346 (Pubitemid 39572916)
92. Tokunaga, Y.; Iwasa, T.; Fujisaki, J.; Sawai, S.; Kagayama, A. Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes Chem. Pharm. Bull. (Tokyo) 1988, 36, 3574-3583
93. Brusa, P.; Immordino, M. L.; Rocco, F.; Cattel, L. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs Anticancer Res. 2007, 27, 195-199
94. Sloat, B. R.; Sandoval, M. A.; Li, D.; Chung, W.-G.; Lansakara-P, D. S.; Proteau, P. J.; Kiguchi, K.; DiGiovanni, J.; Cui, Z. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharmaceutics 2011, 409, 278-288
95. Chung, W.-G.; Sandoval, M. A.; Sloat, B. R.; Lansakara-P, D. S.; Cui, Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1 J. Controlled Release 2012, 157, 132-140
96. Sandoval, M. A.; Sloat, B. R.; Lansakara-P, D. S.; Kumar, A.; Rodriguez, B. L.; Kiguchi, K.; DiGiovanni, J.; Cui, Z. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity J. Controlled Release 2012, 157, 287-296
97. Batrakova, E. V. Sensitizing of gemcitabine-resistant human leukemia cells by stearoyl gemcitabine nanoparticles Nanomedicine (London) 2011, 6, 1491-1492
98. Nicholson, R. I.; Gee, J. M.; Harper, M. E. EGFR and cancer prognosis Eur. J. Cancer 2001, 37, S9-S15 (Pubitemid 32938124)
99. Yokoyama, T.; Tam, J.; Kuroda, S.; Scott, A. W.; Aaron, J.; Larson, T.; Shanker, M.; Correa, A. M.; Kondo, S.; Roth, J. A.; Sokolov, K.; Ramesh, R. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells PLoS ONE 2011, 6, e25507
100. Song, S.; Liu, D.; Peng, J.; Sun, Y.; Li, Z.; Gu, J.-R.; Xu, Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo Int. J. Pharmaceutics 2008, 363, 155-161
101. Gao, J.; Yu, Y.; Zhang, Y.; Song, J.; Chen, H.; Li, W.; Qian, W.; Deng, L.; Kou, G.; Chen, J.; Guo, Y. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma Biomaterials 2012, 33, 270-282
102. Benhabbour, S. R.; Luft, J. C.; Kim, D.; Jain, A.; Wadhwa, S.; Parrott, M. C.; Liu, R.; DeSimone, J. M.; Mumper, R. J. In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain J. Controlled Release 2011, 158, 63-71
103. Bergman, A. M.; Adema, A. D.; Balzarini, J.; Bruheim, S.; Fichtner, I.; Noordhuis, P.; Fodstad, O.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models Invest. New Drugs 2011, 29, 456-466
104. Adema, A. D.; Bijnsdorp, I. V.; Sandvold, M. L.; Verheul, H. M.; Peters, G. J. Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer Curr. Med. Chem. 2009, 16, 4632-4643
105. Breistøl, K.; Balzarini, J.; Sandvold, M. L.; Myhren, F.; Martinsen, M.; De Clercq, E.; Fodstad, O. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models Cancer Res. 1999, 59, 2944-2949 (Pubitemid 29283136)
106. ELACYT Clinical Update-Clavis Pharma. http://www.clavispharma.com/news- events/2008-press-releases/elacyt-clinical-update (accessed Jan 4, 2012).
107. Dueland, S.; Aamdal, S.; Lind, M. J.; Thomas, H.; Sandvold, M. L.; Gaullier, J.-M.; Rasch, W. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study Acta Oncol. 2009, 48, 137-145
108. Pignata, S.; Amant, F.; Scambia, G.; Sorio, R.; Breda, E.; Rasch, W.; Hernes, K.; Pisano, C.; Leunen, K.; Lorusso, D.; Cannella, L.; Vergote, I. A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy Cancer Chemother. Pharmacol. 2011, 68, 1347-1353
109. Adema, A. D.; Smid, K.; Losekoot, N.; Honeywell, R. J.; Verheul, H. M.; Myhren, F.; Sandvold, M. L.; Peters, G. J. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126 Invest. New Drugs 2012, 30, 1908-1916
110. Galmarini, C. M.; Myhren, F.; Sandvold, M. L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines Br. J. Hamaetol. 2009, 144, 273-275
111. Sandvold, M. L.; Galmarini, C.; Myhren, F.; Peters, G. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues Nucleosides Nucleotides Nucleic Acids 2010, 29, 386-393
112. Gagnadoux, F.; Le Pape, A.; Urban, T.; Montharu, J.; Vecellio, L.; Dubus, J.-C.; Leblond, V.; Diot, P.; Grimbert, D.; Racineux, J.-L.; Lemarié, E. Safety of pulmonary administration of gemcitabine in rats J. Aerosol Med. 2005, 18, 198-206 (Pubitemid 40911360)
113. Adema, A. D.; Laan, A. C.; Myhren, F.; Fichtner, I.; Verheul, H. M.; Sandvold, M. L.; Peters, G. J. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel Int. J. Oncol. 2010, 36, 285-294
114. Ali, S. M.; Khan, A. R.; Ahmad, M. U.; Chen, P.; Sheikh, S.; Ahmad, I. Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002) Bioorg. Med. Chem. Lett. 2005, 15, 2571-2574 (Pubitemid 40626732)
115. Sakamoto, T.; Inoue, T.; Otomo, Y.; Yokomori, N.; Ohno, M.; Arai, H.; Nakagawa, Y. Deficiency of cardiolipin synthase causes abnormal mitochondrial function and morphology in germ cells of Caenorhabditis elegans J. Biol. Chem. 2012, 287, 4590-4601
116. Chien, P.-Y.; Khan, A. R.; Miller, B.; Sheikh, S.; Ali, S. M.; Ahmad, M. U.; Ahmad, I. A novel gemcitabine-cardiolipin conjugate induced cytotoxicity in cancer cells through an equilibrative nucleoside transporter-independent pathway. AACR Meeting Abstracts 2005, not supplied.
117. Chen, P.; Chien, P.-Y.; Khan, A. R.; Sheikh, S.; Ali, S. M.; Ahmad, M. U.; Ahmad, I. In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate Anticancer Drugs 2006, 17, 53-61
118. Galmarini, C. M.; Warren, G.; Senanayake, M. T.; Vinogradov, S. V. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs Int. J. Pharmaceutics 2010, 395, 281-289
119. Bazzanini, R.; Manfredini, S.; Durini, E.; Gröschel, B.; Cinatl, J.; Balzarini, J.; De Clercq, E.; Imbach, J. L.; Périgaud, C.; Gosselin, G. Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation Nucleosides Nucleotides 1999, 18, 971-972 (Pubitemid 29320646)
120. Tobias, S. C.; Borch, R. F. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs J. Med. Chem. 2001, 44, 4475-4480 (Pubitemid 33131672)
121. Perigaud, C.; Peyrottes, S.; Dumontet, C. Gemcitabine phosphoester prodrugs as anticancer agents. Patent Application WO/2009/053654, 2009.
122. Vande Voorde, J.; Liekens, S.; McGuigan, C.; Murziani, P. G.; Slusarczyk, M.; Balzarini, J. The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes Biochem. Pharmacol. 2011, 82, 441-452
123. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang, J.; Muhammad, J.; Patti, J. M.; Henson, G. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus Bioorg. Med. Chem. Lett. 2010, 20, 4850-4854
124. Vernachio, J. H.; Bleiman, B.; Bryant, K. D.; Chamberlain, S.; Hunley, D.; Hutchins, J.; Ames, B.; Gorovits, E.; Ganguly, B.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, N.; Walters, C. R.; Wang, J.; Williams, K.; Patti, J. M.; Henson, G.; Madela, K.; Aljarah, M.; Gilles, A. McGuigan, C. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties Antimicrob. Agents Chemother. 2011, 55, 1843-1851
125. Tobias, S. C.; Borch, R. F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug Mol. Pharmaceutics 2004, 1, 112-116
126. Mehellou, Y.; Valente, R.; Mottram, H.; Walsby, E.; Mills, K. I.; Balzarini, J.; McGuigan, C. Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism Bioorg. Med. Chem. 2010, 18, 2439-2446
127. Wu, W.; Sigmond, J.; Peters, G. J.; Borch, R. F. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug J. Med. Chem. 2007, 50, 3743-3746 (Pubitemid 47195480)
128. Burris, H. A., III; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 1997, 15, 2403-2413 (Pubitemid 27251144)